Muscular Dystrophy Clinical Trials

A listing of Muscular Dystrophy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
A Phase 2 Randomized Controlled Dose-titration Open-Label Study Evaluating the Safety and Efficacy of BIV201 in Addition to Standard of Care Compared to Standard of Care to Reduce the Recurrence of Ascites and Complications in Patients with Refractory Ascites Secondary to Decompensated Liver Cirrhosis

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 3 Randomized Double-blind Placebo-controlled Study to Assess the Efficacy and Safety of BIVV009 in Patients with Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion (Cadenza)

This is a randomized, double-blind, placebo-controlled, multicenter study in patients with primary cold agglutinin disease (CAgD) without a recent history of blood transfusion. Eligible patients will receive study drug (BIVV009 or placebo) and undergo safety and efficacy assessments for 6 months (26 weeks) during Part A. Following completion of the …

  • 0 views
  • 19 Feb, 2024
  • 1 location
An Open-label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder (TreT) in Subjects with Pulmonary Arterial Hypertension Currently Using Tyvaso

This Phase 1b, open-label, multicenter study will be conducted to evaluate the safety and tolerability of treprostinil inhalation powder (TreT) in subjects with PAH currently ssing Tyvaso. A minimum of 45 patients from 15 sites in the US will be enrolled in the study.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Clinical Trial to Evaluate the Safety and Efficacy of Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor

The Exablate Model 4000 Type-1.0/1.1 Neuro system involves using an advanced, non-invasive technique currently approved by the Food and Drug Administration (FDA) to treat one side of your brain in a procedure called a thalamotomy (lesion the thalamus). This procedure involves performing an ablation (lesion) of an area of the …

  • 0 views
  • 19 Feb, 2024
  • 1 location
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on Recovery (DISCOVERY)

TBD

  • 0 views
  • 19 Feb, 2024
  • 1 location
Patient-directed messaging to increase colorectal cancer screening

See attached form

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 26417: A Phase 1/2a Open-label Study to Investigate the Safety and Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-573 (formerly TEV-48573) Administered Intravenously as a Single Agent in Patients with Refractory Multiple Myeloma

Request for collaborative review: WIRB serving as IRB of record.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Zoster Eye Disease Study (ZEDS): A multi-center randomized double-masked placebo-controlled study of valacyclovir in immunocompetent subjects with a history of dendriform epithelial keratitis stromal keratitis endothelial keratitis and/or iritis due to Herpes Zoster Ophthalmicus (HZO) within the year prior to enrollment.

Request to rely on the lead site IRB, see attached documents

  • 0 views
  • 19 Feb, 2024
  • 1 location
AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Reliance Agreement Request

  • 0 views
  • 19 Feb, 2024
  • 1 location
UPCC 19418: A Phase 1/2a Dose-Finding Study of PT-112 in Patients with Relapsed or Refractory Multiple Myeloma

Multicenter, open-label study of PT-112 in patients with relapsed/refractory MM. The study will be conducted in two parts. The first part of the study involves dose-escalation, in which successive cohorts of patients will receive escalating doses of PT-112 until the maximum tolerated dose (MTD) is reached. The second part of …

  • 0 views
  • 19 Feb, 2024
  • 1 location